Longevity PapersAbout
← All papers
RESEARCH PAPER / 2025-10-07

Methionine restriction and mimetics to ameliorate human aging and disease.

Andrey A Parkhitko, Sudipta Pathak, Jay E Johnson, Bettina Mittendorfer, Matthew L Steinhauser

Aging Institute of UPMC and the University of Pittsburgh, Pittsburgh, PA, USA; Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: [email protected]. · pubmed

Abstract

Methionine restriction (MetR) attenuates the severity of numerous age-related diseases and extends lifespan across multiple species. Implementing MetR in humans remains challenging due to the low palatability of MetR diets, unfavorable side effects associated with continuous dietary MetR, and interindividual variation in factors that can diminish its efficacy, including microbiota activity, compensatory effects from cysteine, and methionine transfer from neighboring cells. Several novel approaches that target methionine metabolism have been developed - including small molecules, synthetic biotics, and xenotopic tools - with some already translated into early-stage clinical trials. In this review, we discuss a variety of approaches that either produce or mimic MetR, as well as their potential applications for human healthspan improvement.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses the potential of methionine restriction and its mimetics to improve human healthspan and mitigate age-related diseases. This research is relevant as it addresses mechanisms that could directly influence the aging process and lifespan extension rather than merely treating symptoms of age-related conditions.

Author of this paper? Send a correction.